Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma

Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma

“Lomustine has been shown to have single-agent activity in recurrent glioblastoma, and nitrosoureas are well known to readily penetrate the bloodbrain barrier,” Gilbert wrote. “Therefore, the failure of other agents, such as irinotecan, to show

(Visited 2 times, 1 visits today)
14
Like
Save

Comments

Comments are disabled for this post.